- Home
- GLPG
GLPG
Galapagos NV
as 02-21-2025 4:00pm EST
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
| Founded: | 1999 | Country: | Belgium |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.8B | IPO Year: | 2005 |
| Target Price: | $26.75 | AVG Volume (30 days): | 354.0K |
| Analyst Decision: | Sell | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.16 | EPS Growth: | -65.14 |
| 52 Week Low/High: | $22.36 - $38.01 | Next Earning Date: | 02-12-2025 |
| Revenue: | $285,380,474 | Revenue Growth: | 14.99% |
| Revenue Growth (this year): | 2.78% | Revenue Growth (next year): | 1.62% |
Latest Galapagos NV News
GLPG Breaking Stock News: Dive into GLPG Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Galapagos (AMS:GLPG) adds €185m to market cap in the past 7 days, though investors from five years ago are still down 89%
GlobeNewswire
5 days ago
Galapagos receives transparency notification and 13D filing from Tang Capital
MT Newswires
8 days ago
Morgan Stanley Downgrades Galapagos to Underweight From Equal Weight, Adjusts Price Target to $22 From $31
GuruFocus.com
9 days ago
Galapagos NV (GLPG) (FY 2024) Earnings Call Highlights: Strategic Shifts and Financial Resilience
GlobeNewswire
10 days ago
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
Insider Monkey
10 days ago
Galapagos NV (GLPG): A Cheap Biotech Stock to Invest In Now
Zacks
17 days ago
Galapagos (GLPG) Loses -21.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
MT Newswires
a month ago
Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%
Compare GLPG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLPG Galapagos NV - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.